Pfizer Stock - Analyst consensus and valuation snapshot
Published on 06/22/2026 at 14:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 14:49 UTC. Details in the imprint.
Pfizer (US7170811035) trades well below its pre-pandemic highs while Wall Street maintains a broadly constructive view on the stock. Consensus data from several broker platforms indicate a moderate-buy stance with upside potential based on pipeline optionality and cost-cutting progress, according to current analyst overviews.
All news and analysis on Pfizer stock
Pfizer remains heavily covered by brokers and media; our topic page aggregates current headlines, quotes and background on the New York-listed pharma stock.
What current consensus shows
Across major platforms, Pfizer stock is currently characterized as a "moderate buy" based on aggregated broker recommendations. One consensus overview cites an average 12-month price target near $29.50, implying mid-teens percentage upside from recent levels, according to an analyst summary page. An eToro analyst consensus snapshot
The same overview lists a price-to-earnings ratio just below 20 and a dividend yield around the high single digits, underlining that a significant part of the expected return is meant to come from income. The rating spread typically skews towards buys and holds, with only a minority of explicit sell recommendations.
How the market prices Pfizer
Recent quote data place Pfizer shares in the mid-$20s, keeping the stock near multi-year lows and well off the 2021 pandemic peak above $50. One real-time retail brokerage quote shows the shares around $25.25, implying a market value near $144 billion. A Robinhood price and market cap overview
At these levels, the dividend yield stands in a high single-digit range, which is elevated versus many large-cap pharma peers. Valuation metrics such as forward earnings and cash flow multiples therefore reflect both the revenue cliff after COVID products and expectations that pipeline launches and cost cuts can gradually rebuild earnings.
Tuesday lens on analyst updates
From a Tuesday perspective, the focus lies on how analyst sentiment and estimates evolve rather than on a single rating move. Consensus still embeds a recovery path for earnings through the late 2020s, supported by management's stated plan to offset the post-pandemic revenue decline with new launches and productivity gains. Pfizer's quarterly reporting materials
Estimate revisions over the past quarters have generally been downward for near-term revenues as COVID vaccine demand normalizes, while longer-term projections depend heavily on execution in oncology, immunology and infectious diseases. Against this backdrop, investors should keep an eye on how upcoming trial readouts or regulatory decisions might trigger fresh target changes.
What the company sells
Pfizer generates revenue from a broad portfolio of prescription medicines and vaccines, including products in oncology, rare diseases, inflammation and immunology, internal medicine and hospital injectables. A widely known example from its current lineup is the pneumococcal vaccine Prevnar 20, alongside its COVID offerings Comirnaty and Paxlovid.
Where the stock trades today
Pfizer shares (US7170811035) trade on the New York Stock Exchange at approximately $25.25 as of 06/22/2026, 14:30 UTC.
Key facts on Pfizer stock
- Company: Pfizer Inc.
- ISIN: US7170811035
- WKN: 852009
- Ticker: PFE
- Venue: NYSE
- Price (as of 06/22/2026, 14:30 UTC): 25.25 USD
- Market cap: 143,700,000,000 USD (as of 06/22/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
